Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 1.120B
March 31, 2026 631.20M
December 31, 2025 168.20M
September 30, 2025 623.70M
June 30, 2025 1.03B
March 31, 2025 980.80M
December 31, 2024 882.10M
September 30, 2024 480.40M
June 30, 2024 166.30M
March 31, 2024 -390.80M
December 31, 2023 -12.00M
September 30, 2023 277.90M
June 30, 2023 598.10M
March 31, 2023 225.50M
December 31, 2022 58.50M
September 30, 2022 616.10M
June 30, 2022 52.20M
March 31, 2022 -163.50M
December 31, 2021 324.20M
September 30, 2021 -655.00M
June 30, 2021 92.00M
March 31, 2021 211.90M
December 31, 2020 277.00M
September 30, 2020 -211.00M
June 30, 2020 3.696B
Date Value
March 31, 2020 -490.70M
December 31, 2019 198.20M
September 30, 2019 11.00M
June 30, 2019 -14.50M
March 31, 2019 -130.60M
December 31, 2018 -27.07M
September 30, 2018 -48.96M
June 30, 2018 -20.65M
March 31, 2018 -13.43M
December 31, 2017 -13.32M
September 30, 2017 -38.20M
June 30, 2017 -172.02M
March 31, 2017 -16.67M
December 31, 2016 -36.96M
September 30, 2016 -26.17M
June 30, 2016 -24.30M
March 31, 2016 -39.30M
December 31, 2015 -55.94M
September 30, 2015 -34.60M
June 30, 2015 -39.55M
March 31, 2015 -76.27M
December 31, 2014 -45.24M
September 30, 2014 -17.75M
June 30, 2014 -8.015M
March 31, 2014 -55.04M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. -33.56M
AbbVie, Inc. 9.00M
Gilead Sciences, Inc. 346.00M
Amgen, Inc. 0.00
Biogen, Inc. -6.00M